Recent advances and impending challenges for the radiopharmaceutical sciences in oncology Review
| Authors: | Lapi, S. E.; Scott, P. J. H.; Scott, A. M.; Windhorst, A. D.; Zeglis, B. M.; Abdel-Wahab, M.; Baum, R. P.; Buatti, J. M.; Giammarile, F.; Kiess, A. P.; Jalilian, A.; Knoll, P.; Korde, A.; Kunikowska, J.; Lee, S. T.; Paez, D.; Urbain, J. L.; Zhang, J.; Lewis, J. S. |
| Review Title: | Recent advances and impending challenges for the radiopharmaceutical sciences in oncology |
| Abstract: | This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer. © 2024 Elsevier Ltd |
| Keywords: | immunohistochemistry; cancer surgery; unclassified drug; review; capecitabine; cancer radiotherapy; temozolomide; nuclear magnetic resonance imaging; antineoplastic agent; technetium 99m; clinical practice; neoplasm; ovary adenocarcinoma; quality control; cancer immunotherapy; cytotoxicity; molecular imaging; oncology; cancer research; cancer therapy; neuroendocrine tumor; prostate cancer; health insurance; reimbursement; prostate specific membrane antigen; radioactive iodine; dosimetry; artificial intelligence; radioactivity; radiopharmaceutical agent; (3 iodobenzyl)guanidine; octreotide; external beam radiotherapy; radioisotope; tositumomab i 131; science; drug delivery system; somatostatin; personalized medicine; radiochemistry; pancreas islet cell carcinoma; tumor microenvironment; single photon emission computed tomography; lintuzumab; machine learning; lutetium 177; human; male; female; positron emission tomography-computed tomography; girentuximab; theranostic nanomedicine; antineoplastic monoclonal antibody; omburtamab; apamistamab i 131; vipivotide tetraxetan; oxodotreotide lutetium lu 177; edotreotide; fap2286; fpi1434; fpi1966; her2vhh; hurlutin; iodophenylalanine; lilotomab; pnt6555; rosopatamab; ryz101; satoreotide; zadavotide guraxetan lutetium lu 177 |
| Journal Title: | Lancet Oncology |
| Volume: | 25 |
| Issue: | 6 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-06-01 |
| Start Page: | e236 |
| End Page: | e249 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(24)00030-5 |
| PROVIDER: | scopus |
| PUBMED: | 38821098 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work